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Introduction
As the world continues to experience climatic and ecosystem 
changes and increased human migration, there has been a surge 
of novel and re-emerging pathogens. Over the past three decades, 
up to 30 new human pathogens have been detected, 75% of 
which have animal origin (Jones et al., 2008). Rift Valley fever, 
Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-1), 
Pandemic influenza H1N1 2009, Yellow fever, Avian Influenza 
(H5N1 and H7N9), West Nile virus, Middle East Respiratory 
Syndrome Coronavirus (MERS-CoV) and the current Severe 
Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) are a few 
among many (Jones et al., 2008; Mourya et al., 2019).
COVID-19 triggers respiratory difficulties for which the 
SARS-CoV-2 virus is responsible. The virus was first reported in 
the city of Wuhan, Hubei Province, in China on December 31st 
2019 (WHO, 2020). Since then, the virus has wreaked havoc in 
different countries at an alarming pace, claiming thousands of 
lives. As of late March 2020, Africa had not yet recorded as 
many mortalities as Europe, North America and Asia. However, 
the economic impact of the pandemic will not spare the continent. 
It is predicted that the disease will cost the world economy at 
least $1.1 trillion in lost income due to forced quarantine, as 
businesses, schools and factories would have to be closed (Oxford 
Economics, 2020). While high income countries and some 
emerging countries have responded with varying stimulus 
packages for example; United States $2 trillion, France $49 
billion, Australia $11 billion, United Kingdom £350 billion, and 
India $54.2 billion (see Mervis, 2020), Africa, and especially 
the sub-Saharan region, has limited capacity to marshall up such 
stimulus packages. Therefore, there is an urgent need for African 
governments to invest in resilient health systems to ensure robust 
response and post-pandemic economic rejuvenation (Kruk 
et al., 2015).
As the global scientific community works assiduously to limit 
the spreading of COVID-19, the Affiliates of the African Academy 
of Sciences (AAS) have synthesized current evidence on the 
biology and epidemiology of the disease, and identified the chal-
lenges and opportunities in combating the global pandemic. 
This paper aims to enhance understanding of COVID-19, assess 
Africa’s preparedness and determine operational challenges of 
disease control.
Methods
Recognizing the threat of COVID-19 on the continent, 13 scientists 
from eight African countries conducted research on COVID-19, 
in an effort to understand the biology and epidemiology of the 
virus as well as its impacts on and the preparedness of Africa. The 
scientists are from Ghana (n=2), South Africa (n=2), Namibia 
(n=1), Nigeria (n=3), Uganda (n=1), Mauritius (n=1), Kenya 
(n=2) and Egypt (n=1) and their expertise ranged from virology, 
clinical science and medicine, polymer chemistry, public health, 
behavioural science, computational biology, statistics, medical 
statistics, health monitoring and evaluation, environmental 
science, human geography, and engineering.
Three brainstorming sessions via Zoom were conducted. 
Following email exchanges and meetings, four main sub-themes 
were highlighted: (1) nature and biology of the virus, (2) poten-
tial impact of the pandemic on the continent, (3) health systems 
preparedness, and (4) challenges, knowledge gaps and research 
opportunities. The scientists aggregated within sub-groups and 
worked on the identified sub-themes. A consolidation of these 
sub-themes paved the way for recommendations for policy 
and research avenues for the scientific community.
To identify studies, the following sources were used: Scopus 
and Web of Science biographic databases, peer review journals 
of the BMC, Proceedings of the Royal Society of London, 
Lancet, Oxford Academic, medRxiv, National Library of 
Medicine; organizational websites of the World Health 
Organisation, National Centre for Biotechnology, National Insti-
tute for Communicable Diseases, the World Economic Forum, 
Government websites and Google Scholar. Keywords included: 
“COVID-19”, “nature of virus”, “biology”, “genome impacts”, 
“Africa”, “preparedness”, “impacts”, “responses”, among 
others. Overall 300 articles were retrieved out of which 135 
were considered to be relevant for this paper. Inclusion criteria: 
articles had to be directly related to the sub themes i.e., coronavi-
rus, potential impact, preparedness and knowledge gaps as well as 
being current. We excluded articles that were not directly related 
to our sub themes.
Nature and biology of the virus
Biology of the virus
Coronaviruses consist of a lipid envelope containing a positive 
single stranded RNA and are generally characterized by club-like 
spikes projecting from their surface (Phan, 2020). They commonly 
result in respiratory diseases with mild to severe outcomes in 
humans. However, they are particularly complex due to their 
ability to infect multiple host species (Fung & Liu, 2019). 
Coronaviruses are divided into four main sub-groups namely; alpha, 
beta, gamma and delta-coronaviruses. These groups can be found 
in wildlife such as bats (bats coronaviruses) and livestock species 
such as cattle (bovine coronaviruses), goats and sheep (Phan, 
2020). Although several coronaviruses are zoonotic in nature, 
their wide genetic diversity, frequent genomic recombination, and 
increasing human–animal interfacial contact, novel coronaviruses 
capable of human infection (human coronaviruses) are likely to 
periodically emerge.
Within the family of coronaviruses, COVID-19 is the seventh 
known member infecting humans. Since November 2019, six 
coronavirus species were known to cause human diseases with four 
of them in particular: HCoV-229E, HCoV-OC43, HCoV-NL63, 
and HCoV-HKU1 being prevalent and known to cause mild illness 
such as common colds in immunocompetent individuals. The 
two other strains namely SARS-CoV-1 and MERS-CoV, both 
zoonotic in origin, attracted worldwide attention, by causing severe 
respiratory disease outbreaks and fatalities in 2003 and 2014–15 
respectively (Lo et al., 2005; Oboho et al., 2015). COVID-19 
has a closer resemblance to SARS-CoV-1 than MERS-CoV. 
Both SARS-CoV-1 and MERS-CoV epidemics subsided 
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following much less drastic measures than those being currently 
implemented in the fight against COVID-19, which is evidently 
highly transmissible and more virulent.
The length of the genome of coronaviruses ranges from approxi-
mately 26,000 to 32,000 bases with varying numbers of open 
reading frames (ORFs) (from 6–11) (Song et al., 2019). Non- 
structural proteins (NSPs) comprise approximately 67% of the 
entire genome, while the remaining ORFs encode accessory and 
structural proteins (Cui et al., 2019). The four major structural 
proteins of coronaviruses are the spike surface glycoprotein (S), 
small envelope protein (E), matrix protein (M), and nucleocapsid 
protein (N).
In late 2019, viral metagenomics analysis that was conducted on 
bronchoalveolar-lavage specimens from early infected Chinese 
adult patients confirmed the mismatch with known pathogenic 
coronaviruses (HCoV-229E, HCoV-NL63, HCoV-OC43, and 
HCoV-HKU1) (Zhu et al., 2020). This confirmed that the dis-
ease was caused by a novel coronavirus. Genomic sequencing 
showed that the novel virus shared more than 85% similarity with 
a bat SARS-like CoV (bat-SL-CoVZC45 and bat-SL-CoVZXC21) 
with the majority of the contigs matching the genome from 
lineage B of the genus betacoronavirus (Zhu et al., 2020). This 
was confirmed by real-time RT-PCR assay matching the viral 
RNA to a consensus RdRp region of pan B-CoV. The COVID-19 
genome has 14 ORFs encoding 27 proteins. Found at the 
5`-terminus of the genome, the orf1ab and orf1a genes encode 
the pp1ab and pp1a proteins, respectively. Together, they consist 
of 15 nsps including nsp1 to nsp10 and nsp12 to nsp16. The 
3`-terminus of the genome contains four structural proteins 
(S, E, M, and N) and eight accessory proteins (3a, 3b, p6, 7a, 
7b, 8b, 9b, and orf14) (Figure 1). Recent COVID-19 genomic 
sequence data from multiple patients from different countries 
shows multiple variants with mutational differences indicating 
that the virus continues to evolve in human hosts (Li et al., 2020).
The organization of the genetic material of the COVID-19 
virus resembles that of bat-SL-CoVZC45, bat-SL-CoVZXC21, 
and SARS-CoV-1. In particular, the lengths of the majority of 
Figure 1. Structure of 2019 n-CoV in the prefusion conformation. (A) Schematic of 2019n-CoV primary structure colored by domain. 
Domains that were excluded from the ectodomain expression construct or could not be visualized in the final map are colored white. SS= 
signal sequence, NTD= N-terminal domain, RBD= receptor-binding domain, SD1= subdomain 1, SD2= subdomain 2, S1/S2= S1/S2 protease 
cleavage site, S2`= S2` protease cleavage site, FP= fusion peptide, HR1= heptad repeat 1, CH= central helix, CD= connector domain, HR2= 
heptad repeat 2, TM= transmembrane domain, CT= cytoplasmic tail. Arrows denote protease cleavage sites. (B) Side and top views of the 
prefusion structure of the 2019-nCoV S protein with a single RBD in the up conformation. The prefusion 2019-nCoV spike glycoprotein structure 
(Accession ID 6VSB) was obtained from the publicly available RSCB Protein Data Bank [Reference 1: RCSB Protein Data Bank: Enabling 
biomedical research and drug discovery (2020) Protein Science 29: 52–65 doi: 10.1002/pro.3730]. The 3D structure figure was generated 
using NGL, a web application for molecular visualisation [Reference 2: AS Rose and PW Hildebrand. NGL Viewer: a web application for 
molecular visualization. Nucl Acids Res (1 July 2015) 43 (W1): W576-W579 first published online April 29, 2015. doi:10.1093/nar/gkv402].
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proteins encoded by COVID-19, bat-SL-CoVZC45, and 
bat-SL- CoVZXC21 were found to be identical with few minor 
insertions or deletions. COVID-19 encoded a longer spike pro-
tein compared to the bat SARS-like coronaviruses, SARS-CoV-1, 
and MERS-CoV (Lu et al., 2020).
In terms of amino acid sequences, the COVID-19 virus is close to 
SARS-CoV-1, but there are significant differences. For instance, 
the 8a protein found in SARS-CoV-1 is absent in COVID-19; 
the 8b protein is made up of 84 amino acids in SARS-CoV-1, but 
was found to be longer (121 amino acids) in COVID-19; the 3b 
protein in SARS-CoV-1 consists of 154 amino acids, but is shorter 
in COVID-19, with only 22 amino acids (Wu et al., 2020). The 
overall structure of the spike protein (S) in COVID-19 is very 
similar to that of SARS-CoV-1, with a root mean square deviation 
(RMSD) of 3.8 Angstrom over 959 CA atoms. The main distinc-
tive feature between COVID-19 and SARS-CoV-1 is the position 
of the receptor binding domains (RBDs) in their respective down 
conformations. Indeed, the RBD in SARS-CoV-1 packs tightly 
against the N-terminal domain (NTD) of the neighbouring 
protomer in the down conformation. On the other hand, the RBD 
in COVID-19 in the down conformation is angled closer to the 
central cavity of the trimer. The spike protein of the COVID-19 
shares 98% sequence similarity with that of the bat coronavirus 
RaTG13 (Coutard et al., 2020). Furthermore, the spike protein 
of both COVID-19 and SARS-CoV-1 possess a similar host-cell 
receptor namely angiotensin-converting enzyme 2 (ACE2).
Other unique features of COVID-19 include the insertion in the 
S1/S2 protease cleavage site resulting in an “RRAR” furin 
recognition site in COVID-19 in contrast to the single arginine 
in SARS-CoV-1 (Coutard et al., 2020). Moreover, several key 
residues responsible for the binding of the RBD of SARS-CoV-1 
to the ACE2 receptor were variable in the case of the COVID-19 
(including Asn439, Asn501, Gln493, Gly485 and Phe486; 
2019-nCoV numbering) rationalizing the difference in their 
binding affinities (Lu et al., 2020). Indeed, the binding affinity 
of ACE2 to the COVID-19 ectodomain measured via surface 
plasmon resonance (SPR) was found to be approx. 15 nM which 
is about 10-20 times higher than that of SARS-CoV-1 which 
explains the higher ease of transmission of COVID-19 among 
humans (Coutard et al., 2020). Amino acid examination of 
COVID-19 and SARS-CoV-1 helped to shed light on the structural 
and functional differences of the two coronaviruses. In particular, 
380 amino acid substitutions exist between the amino acid 
sequences of COVID-19 (HB01) and the analogous consensus 
structure of SARS-CoV-1 and SARS-like viruses. Indeed, 102 
and 61 amino acid substitutions were noted in nsp3 and nsp 2 
respectively (Wu et al., 2020). Additionally, there are 29 variant 
residues between the spike protein of COVID-19 and RaTG13 
with 17 positions corresponding to RBDs.
Morphological elucidation via transmission electron microscopy 
(TEM) confirmed that COVID-19 belonged to the Coronaviridae 
family. The virus particles were spherical in general with diam-
eter ranging between 60–140 nm with quite characteristic spikes, 
about 9 to 12 nm (Cascella et al., 2020). Genomic sequencing 
of the COVID-19 showed that the genomes clustered together 
within the sarbecovirus subgenus, with a typical betacoronavirus 
organization: a 5` untranslated region (UTR), replicase complex 
(orf1ab), S gene, E gene, M gene, N gene, 3` UTR, and several 
unidentified nonstructural open reading frames.
Pathogenesis of COVID-19
COVID-19 similar to the SARS-CoV-1 binds the ACE2 receptor 
to gain entry into cells, where it replicates using the cellular 
machinery (Li et al., 2003; Zhou et al., 2020) leading to cell 
injury and death. The ACE2 receptor, though abundant in the 
respiratory system, are also found in other tissues such as 
gastrointestinal, testis and kidney (Li et al., 2020).
Thus, patients with mild disease present with respiratory symptoms 
such as rhinorrhoea, sneezing, and sore throat, and with severe 
disease the lower respiratory tract is involved leading to dif-
ficulty in breathing, shortness of breath, coughing and acute 
respiratory distress syndrome. Gastrointestinal issues, such as 
diarrhoea and abdominal discomfort, as well as kidney failure 
have been noted (Worldometer, 2020. Increasingly, different types 
of clinical and biological evolution have been noted as observed 
by Lescure et al. and Huang et al. in patients infected with 
COVID-19. These include mild, moderate and severe or critical 
with either persistent worsening or biphasic evolution of the 
condition (Huang et al., 2020; Lescure et al., 2020).
The severe clinical sequelae of COVID-19, is attributed to 
immune-inflammatory responses that lead to host tissue injury. 
Patients infected with COVID-19 showed increased levels of 
plasma pro-inflammatory cytokines with concomitant patholo-
gies such as lung infiltrates evidenced by ground glass opacities 
bilaterally on radiological investigation and acute cardiac injury 
(Huang et al., 2020; Rothan & Byrareddy, 2020). The cytokine 
storm that correlates with disease severity in many patients is 
evidenced by significantly high blood levels of IL1-ȕ, IL1RA, 
IL7, IL8, IL9, IL10, basic FGF2, GCSF, GMCSF, IFNȖ, 
IP10, MCP1, MIP1Į, MIP1ȕ, PDGFB, TNFĮ, and VEGFA. 
In more severe patients, high levels of proinflammatory cytokines 
correlated with the need for admission to the intensive care 
unit. These were IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1Į, 
and TNFĮ (Huang et al., 2020).
Evidence is cumulatively pointing to the fact that the clinical 
presentation is heterogeneous in different populations and ages 
(Heymann et al., 2020; Woelfel et al., 2020). Thus, it is important 
to document clinical and biological progression and patterns in 
different populations, ages, and comorbid backgrounds to better 
guide clinical management and decision making.
Challenges and opportunities of the potential 
impacts of COVID-19 in Africa
Africa’s public health infrastructure and capabilities
As a primary defense, in emergencies regarding infectious 
diseases, at the center of global health security are national 
public health infrastructure and capabilities (Sands et al., 2016). 
Each African country should have crisis management plans in 
readiness and involve the international community to activate such 
preparedness when need be. When comparing the aftermath of 
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recent year’s pandemics and epidemics in Africa, including H1N1 
pandemic, the Ebola virus, SARS, and MERS, preparedness is an 
area of concern. Prior to the H1N1 pandemic in 2009, the WHO 
had urged member states to engage in preparedness development 
as new pandemics emerged, affecting humans. A recent study 
conducted in 2018 evaluated within the WHO African region 
the calibre of country preparedness. Out of 47 countries (of all 
54 countries in Africa), evaluation of 35 national pandemic 
preparedness plans occurred. Results revealed that prepared-
ness in South Africa was high at 79%, while Cote d’Ivoire only 
managed 5%. Across the 35 evaluated countries, the composite 
score for pandemic plan completeness was 36%. The overall 
assessment indicated that there were inadequate pandemic pre-
paredness plans on the African continent (Figure 2 and Figure 3, 
Sambala et al., 2018).
Other challenges in African health systems include: poor 
coordination, management and leadership, inadequate human 
resources, and inadequate budget allocations for health (Oleribe 
et al., 2019). There is a dire need to reinforce public health 
infrastructure and capabilities, as well as multi-sectoral coordina-
tion, human capacity, laboratory testing and surveillance systems 
in the aftermath of COVID-19 (Gilbert et al., 2020).
On average, risk communication and preparation was 48%, with 
coordination and partnership having the highest score (49%). 
Prevention and containment was 35%, while surveillance and 
monitoring scored 34% (Figure 3). Case investigation and 
treatment reported 25% and ethical consideration was the 
lowest across the 35 African countries at 14%. The WHO Head 
of Emergency operations in Africa has warned that new cases 
may emerge at any time, but noted that many hospitals would 
not be able to cope with the increased cases for those requiring 
intensive care treatment. As of 30th March 2020, a total of 4,832 
confirmed cases and 155 deaths in Africa (Figure 4, Table 1) 
had occurred (Worldometer, 2020). It is an axiom that lack of 
laboratory reagents and capacity increases turn-around time 
in mass-testing to confirm COVID-19 cases. This delays case 
confirmation and thus disease management.
Many countries have limited intensive care facilities. For 
example, in South Africa, should an outbreak occur, for hospi-
talized patients, it would be a major challenge for public health 
care services to provide 90–100% with the required supplemental 
oxygen, 20–25% of those with severe cases with the required 
intensive care treatment, and 5–10% of these same severe cases 
with the required mechanical ventilation (WHO Interim guidance, 
2020; WHO Euro region, 2020).
Potential impacts on African economies
The COVID-19 pandemic is likely to have a substantive effect 
on African economies. Who will be affected? Casual workers and 
low-wage earners may be the most impacted, including domestic 
workers, leisure and hospitality workers (Devereux, 2020). In 
Figure 2. Composite scores of preparedness plans by country (Sambala et al., 2018).
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Figure 3. Completeness of the preparedness plans of countries by category (Sambala et al., 2018).
particular, employees in informal sector who do not have access 
to paid sick leave may be reluctant to take time off - which 
could put both their families at risk but also lead to the spread 
of the virus (Fine et al., 2020). As has been seen in the case of 
China, quarantine directives may lead to the partial and full shut 
down of factories, plants and daily markets for the manufacture 
of goods and services and sale of food stuffs. Livelihoods, Small 
to Medium Enterprises will also be severely impacted (World 
Bank, 2020). Moreover, restrictions on the free movement of 
people will disrupt economic activity and the hardest hit will be 
the urban poor that thrive on daily wage earnings (Africa Insiders, 
2020). Universities, schools, colleges, and workplaces have been 
closed – shifting to online lectures which also have their own 
challenges (Houlden & Veletsianos, 2020). This may affect 
teachers, lecturers, graduate student assistants and students 
especially those from already vulnerable and marginalised 
communities and income groups (UNESCO, 2020). Most 
international meetings have been affected for example the 26th 
Commonwealth Heads of Government Meeting (CHOGM) 
that was due in June in Kigali, Rwanda has been postponed 
(Shaban, 2020b), other international and local convenings have 
been affected (Leone, 2020). Consequently, travel plans have 
been cancelled affecting many international conferences and 
tech companies and economies relying on conference-linked 
tourism. Moreover, many African economies are closely inter-
linked with China, this will also affect supply chains (African 
Union, 2020). As such, this may lead to a decline in economic 
growth for 2020 across Africa with a long haul recovery proc-
ess. Estimates of global growth were downgraded by forecasts 
of the Organization for Economic Cooperation and Development 
(OECD) in 2020 from 3 % in 2019 to 2.4% in 2020. The Inter-
national Monetary Fund has indicated a similar decline, includ-
ing a 1% decline in the growth of the Chinese economy due to the 
pandemic (Boone, 2020).
Importation risks
Due to closed air traffic links between the affected Chinese 
provinces and African countries, Gilbert et al. (2020) evaluated 
the virus importation risk that each African country may face in 
the spread of the virus. Countries are required to make mandatory 
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Figure 4. Map of Africa showing the distribution of total cases of COVID-19 in African countries. (Worldometer, as of 0920 GMT March 
30th 2020). 
declarations to the WHO annually, of the country’s resources in 
the preparedness for encountering an epidemic, known as State 
Parties self-assessment Annual Reporting (SPAR). The indicator 
list includes: adherence to WHO standards, medical staff, 
legislation, laboratory skills, food safety, emergency organization, 
measure of equipment in healthcare facilities and communication 
to the public (INSERM, 2020). The Infectious Disease Vulner-
ability Index (IDVI) was also taken into account as it influences 
the response to an epidemic, but it is not directly linked to the 
health system. Both IDVI and SPAR high scores (out of 100 
each), can predict efficient virus importation response. Results 
indicated that South Africa, Algeria and Egypt were most at risk 
of virus importation due to the high trade exchange volume with 
China. Ironically, the SPAR and IDVI scores of these three counties 
were the best on the continent. Kenya, Ghana, Nigeria, Ethiopia, 
Angola, Sudan and Tanzania have lower virus importation risk, 
yet they had lower SPAR and IDVI scores. This raises concern of 
possible non-detection of imported cases or even of local/ 
community and/or national virus spread (INSERM, 2020). This 
points to limited regional and national systems and capacities for 
monitoring and coordination.
Overburdened health care workers and their patients
As is the case in many parts of Africa, hospitals have a limited 
bed capacity to accommodate COVID-19 patients. For example, 
the Lagos State Infectious Disease Hospital (IDH) in Nigeria 
has a 100-bed capacity but has to accommodate a state with over 
18 million residents. In South Africa, nationally there are 187 beds 
per 100,000 population (Dell & Kahn, 2017). Similarly, in many 
African countries, hospitals are understaffed, without enough 
personal protection equipment (PPE), appropriate equipment, 
without training to deal with this novel virus, or unable to 
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Table 1. Distribution of total cases, total deaths, total recoveries, cases and deaths. per one 
million population and date of first reported cases of COVID-19 in African countries (Worldometer, 
as of 0920 GMT March 30th 2020).
Country Total 
cases
Total 
deaths
Total 
recovered
Active 
cases
Cases / 1m 
population
Deaths/1m 
population
Reported 
1st case 
in 2020
South Africa 1,280 2 31 1,247 22 0.03 Mar-04
Egypt 609 40 132 437 6 0.4 Feb-13
Morocco 516 27 13 476 14 0.7 Mar-01
Algeria 511 31 31 449 12 0.7 Feb-24
Burkina Faso 222 12 23 187 11 0.6 Mar-08
Ivory Coast 165 1 4 160 6 0.04 Mar-10
Ghana 152 5 2 145 5 0.2 Mar-11
Senegal 142 NA 27 115 8 NA Mar-01
Cameroon 139 6 5 128 5 0.2 Mar-05
Nigeria 111 1 3 107 0.5 NA Feb-27
Mauritius 110 3 NA 107 86 2 Mar-17
DRC 81 8 2 71 0.9 0.09 Mar-09
Rwanda 70 NA NA 70 5 NA Mar-13
Kenya 42 1 1 40 0.8 0.02 Mar-12
Madagascar 39 NA NA 39 1 NA Mar-19
Uganda 33 NA NA 33 0.7 NA Mar-20
Togo 30 1 1 28 4 0.1 Mar-05
Zambia 29 NA NA 29 2 NA Mar-17
Ethiopia 21 NA 1 20 0.2 NA Mar-12
Congo 19 NA NA 19 3 NA Mar-14
Mali 18 1 NA 17 0.9 0.05 Mar-24
Niger 18 1 NA 17 0.7 0.04 Mar-18
Guinea 16 NA NA 16 1 NA Mar-12
Equatorial 
Guinea
12 NA NA 12 9 NA Mar-13
Eritrea 12 NA NA 12 3 NA Mar-20
Namibia 11 NA 2 9 4 NA Mar-13
Eswatini 9 NA NA 9 8 NA Mar-13
Libya 8 NA NA 8 1 NA Mar-23
Mozambique 8 NA NA 8 0.3 NA Mar-21
Angola 7 2 NA 5 0.2 0.06 Mar-19
Gabon 7 1 NA 6 3 0.4 Mar-12
Zimbabwe 7 1 NA 6 0.5 0.07 Mar-19
Benin 6 NA NA 6 0.5 NA Mar-15
Cabo Verde 6 1 NA 5 11 2 Mar-19
Sudan 6 1 NA 5 0.1 0.02 Mar-12
Mauritania 5 NA 2 3 1 NA Mar-12
Gambia 4 1 NA 3 2 0.4 Mar-16
CAR 3 NA NA 3 0.6 NA Mar-14
Chad 3 NA NA 3 0.2 NA Mar-18
Liberia 3 NA NA 3 0.6 NA Mar-15
Somalia 3 NA NA 3 0.2 NA Mar-15
Guinea-
Bissau
2 NA NA 2 1 NA Mar-24
Total 4,495 147 280 4,079
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handle the number of patients at one time (Finnan, 2020). 
Limited budgets for emergency spending, complicated national 
procurement and recruitment processes and systems compli-
cate the potential for quickly bridging the observed gaps in 
requisite equipment, logistics and staffing (Bruton & Edwards, 
2020; Dusseljee, 2020). These inadequacies and challenges have 
led to protests among health workers in some countries as has 
been the case in Malawi (Pensulo, 2020). All these issues point 
to the need for African countries to improve the functionality of 
their health systems in response to the COVID-19 outbreak to 
increase their capacity to manage a large number of patients 
(McVeigh & Boseley, 2020).
Isolation of poor and rural communities with limited access 
to telecommunications
With the ongoing pandemic, online shopping might increase 
along with deepening Internet penetration, rise in e-commerce and 
more smartphones and mobile payment systems across Africa. 
Nevertheless, many regions remain isolated from internet access 
with high poverty, illiteracy, a lack of transport infrastructure 
and logistical inefficiencies. For example, even in one of the 
continent’s strongest economies, the Internet is utilized by only 
11.5% of South Africa’s population (Makhitha & Dlodlo, 2014). 
If the world becomes more dependent on teleconferencing 
facilities for enterprises, those without access to internet 
infrastructure in many parts of Africa or who have regular inter-
ruptions of communications and power cuts could be increasingly 
isolated.
Adverse impacts on mental health
Rapid implementation of social distancing could cause loneliness 
and isolation of the elderly, people with disabilities and with 
underlying health issues. This could lead to the infliction of 
physical and mental harm, increased anxiety and change daily 
routines for many vulnerable sections of the population. Senior 
citizens’ centers may also be closed. The banning of public 
funerals could also be a source of depression for some of African 
societies, such as in Ghana where these practices are a central 
component of social life (BBC, 2020). Those living with mental 
health disabilities, such as depression, anxiety or post traumatic 
stress disorder (PTSD) may be seriously impacted with a change 
of behaviour, with the closure of schools, businesses and social 
distancing measures (Cassata, 2020).
Food insecurity
Many lower-income communities rely on income received daily 
to survive. The virus could also impact such food insecure 
populations especially among urban poor and mobile populations 
such as camp labourers. In eastern and northern Uganda for 
example, the price of 500 g of salt has been reported to have 
risen by more than fivefold from UGX 700 ($0.19) to UGX4000 
($1.09) within a period of two weeks from the confirmation of 
COVID-19 cases in the country (Rashul et al., 2020). The food 
and agricultural sector may face illness-related labour shortages, 
transport interruptions, and quarantine measures limiting access 
to markets. Furthermore, supply chain disruptions could result 
in food loss and waste. A loss in purchasing power could reduce 
people’s eating patterns, causing nutritional deficits (Beltrami, 
2020). With a potential economic downturn globally, residents 
in poor countries which rely on imports for food and fuel needs 
may see an increase in costs, with a lower export of primary 
commodities. Agriculturally dependent economies, especially in 
sub-Saharan Africa, will likely see a depreciation in their local 
currencies against the United States dollar and worsening balance 
of payment regimes as agricultural exports constrict.
High vulnerability of informal settlements
In densely populated informal settlements across Africa, which 
comprise 59% of urban settlements across Africa (UN-HABITAT, 
2019), the risk of contracting and spreading COVID-19 will be 
very high. Typically, hundreds share communal taps, many rely 
on open defecation without access to functioning toilets, there 
are raw sewerage and open drains, congestion and a lack of 
solid waste management and many diverse nationalities. Physi-
cal contact in informal settlements has a pronounced influence 
on the spread  of respiratory diseases, especially in places with a 
high prevalence of tuberculosis and HIV/AIDs. This will make 
distancing strategies and control interventions within those com-
munities challenging (Johnstone-Robertson et al., 2011). Further, 
prevention materials such as hand sanitizers, masks and other 
detergents have lately seen a spike in prices owing to heightened 
demand. Persons in informal settlements often have limited dis-
posal income and prioritise to secure household basic needs 
especially food, this leaves them more exposed to the risk 
contracting and being agents of COVID-19 spread.
Social services and legal protection
Many services for psychological support, prevention of domestic 
violence, and actions to initiate new protection orders, will no 
longer be offered during national lockdowns. Support groups 
will likely be cancelled, along with home visits, in-person 
assessment and counselling services. Similarly, educational 
workshops and other awareness raising activities will be cancelled. 
This could have particular implications for the increased inci-
dence of domestic and gender-based violence for vulnerable 
women and children (Mosaic, 2020). Further, countries where 
restrictions on movement have been imposed (in part or in full) 
have affected delivery of social services to vulnerable groups for 
examples, persons living with HIV/AIDs face heightened cases 
of discrimination and stigma and an increased difficulty in 
accessing routine services. These incidents have been reported in 
Kenya, South Africa and Uganda (Human Rights Watch, 2020; 
Jerving, 2020).
A potential rise in xenophobia and security
Racism and xenophobia related to COVID-19 could rise with 
the spread of rumors and fake news, fears and stigma, especially 
on social media platforms. For example, in Kenya, recent cases 
have been reported against Asian men and women. Similarly, in a 
Chinese-led hospital in Zambia, suspicion was heightened when 
people returning from China with the virus symptoms were not 
quarantined. Other concerns were raised at hospitals, close to the 
Congo border, where many Chinese companies operate mines 
(STAT, 2020). It is also interesting to note that even outside 
Africa, Mr. Matteo Salvini, former Deputy Prime Minister of 
Italy, wrongly linked COVID-19 to African asylum seekers, 
calling for border closures (Devakumar et al., 2020). For this 
reason, in March 2020, Michelle Bachelet, the UN High 
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Commissioner for Human Rights called on member states to 
combat discrimination triggered by the virus on people of Chinese 
and East Asian ethnicity (Shields, 2020).
Ongoing clinical trials
Currently, not many countries (only 1 in the African conti-
nent) have joined the Solidarity trial: a large international 
trial, launched by WHO aimed to determine the most efficient 
treatment options against COVID-19 (Nature website, Retrieved 
21 April 2020). Argentina, Bahrain, Canada, France, Iran, Norway, 
South Africa, Spain, Switzerland and Thailand. The four most 
promising COVID-19 drug(s) are under investigation in the 
trial: (i) Remdesivir, (ii) the combined use of two HIV drugs, 
Lopinavir/Ritonavir, (iii) a combination of Lopinavir/Ritonavir 
with interferon beta and (iv) the anti-malarial medications Chlo-
roquine and Hydroxychloroquine (WHO, 20202g). Unlike 
conventional clinical trials, the Solidarity trial is very simple 
and does not place additional burden on front line healthcare 
workers but enables collection of data on patients’ response to the 
drugs.
HIV drugs, serum, stem cells and traditional Chinese 
medicine
More than 80 clinical trials are ongoing or pending in China on 
potential treatments for nCov2019. WHO is drafting a clinical 
trials protocol which researchers around the world could use to 
help set similar standards for the trials in China. Some of the trials 
include as many as 600 patients. According to the Chinese 
Clinical Trials Registry, clinical trials involving the use of an 
HIV-drug combination (lopinavir and ritonavir) together with 
another antiviral called remdesivir have already begun (Maxmen, 
2020). Lopinavir and ritonavir block enzymes preventing viral 
replication while Remdesivir is an adenosine analogue developed 
by the US company, Gilead which incorporates nascent viral 
RNA chains causing pre-mature termination. Remdesivir was 
recently shown to possess EC50 = 0.77 µM in Vero E6 cells (Wang 
et al., 2020).
A few clinical trials have also been launched to test the efficacy 
of the antimalarial drug Chloroquine (ChiCTR2000029609). In 
particular, it is currently being tested at more than ten hospitals 
in Beijing and Guangdong province. Another Chinese clinical 
trial involves using plasma from convalescent patients with the 
hypothesis of using the antibodies built up by the persons to fight 
the virus (ChiCTR2000029850). In a stem cell clinical trial listed 
in the Chinese registry, a research team from the First Affiliated 
Hospital of Zhejiang University is looking at injecting stem 
cells isolated from menstrual blood into patients, and compar-
ing results with the placebo group (ChiCTR2000029606). A 
large number of Chinese clinical trials are looking at the poten-
tial of Chinese traditional medicine to treat COVID-19 with 
Shuanghuanglian, being the most popular Chinese medicine 
under investigation (Maxmen, 2020).
The antiviral drug Favilavir (Favipiravir) produced by Zhejiang 
Hisun Pharmaceutical has been approved as an investigational 
therapy in the treatment of COVID-19, reported local media 
(Clinicals Trials Arena. Accessed 01/04/2020). Favilavir is 
approved for the treatment of influenza (Wang et al., 2020). 
COVID-19 infected patients have been recruited in randomized 
clinical trials to investigate the potential of favipiravir in combi-
nation with interferon-A (ChiCTR2000029600) and favipiravir 
combined with baloxavir marboxil (an approved influenza inhibitor 
targeting the cap-dependent endonuclease) (ChiCTR2000029544) 
(Li & De Clercq, 2020) for COVID19 treatment.
So far, Remdesivir, Favilavir and Chloroquine seem more 
promising. Favilavir was found to be 100% effective in protecting 
mice against Ebola virus challenge, although its EC50 value in 
Vero E6 cells was as high as 67µM (Wang et al., 2020). Rem-
desivir and chloroquine blocked viral infection at much lower 
concentrations and displayed high selectivity indices (Wang 
et al., 2020) (Figure 5). A recent clinical trial showed that the 
combination of azithromycin and hydroxychloroquine resulted 
in significantly better COVID-19 viral elimination (Gautret 
et al., 2020). Data from completed and ongoing clinical trials may 
be used as a guide for COVID-19 treatment strategies.
Environmental impacts
Changes in behavior patterns brought on by COVID-19 could 
reduce carbon emissions. Changes may reduce the need for 
long-haul flights, and promote online meetings, working from 
home and habits which reduce commuting. Similarly, with the 
closure of certain supermarkets, consumption might decline. 
Overall, this may mean 2020 will see less CO2 emissions. For 
example, in China, compared to previous years, the lockdown 
led to the 25% reduction in energy use and emissions over a 
two-week period (mostly electricity use, industrial production 
and transport) (Myllyvirta, 2020). Meanwhile, coal consumption 
by the six largest power plants in China has fallen by over 
40% since the last financial quarter (Grant & Larsen, 2019). 
Similar reductions are being observed in Italy and other parts 
of Europe and across the United States of America. The airline 
industry, which covers 2.6% of the global carbon emissions 
will reduce activity, potentially for some period due to the 
lingering period of the virus. A drop in global emissions of 0.3% 
in 2020 is still likely, reports researchers at the Climate and 
Environment Research in Oslo. This is less distinct compared to 
the crash of 2008–09, but also provides an opportunity for less 
rebound if efforts to stimulate the economy are focused 
towards sectors such as clean energy (Henriques, 2020). 
However, whether these will have lasting positive 
environmental impacts remains to be seen. For example, the 
focus on COVID-19 has stalled progress on other policy priorities 
including liberalisation and environmental policies, and a 
further delay may be due to a strong fossil-fuel heavy stimulus 
(Oxford Institute for Energy Studies, 2020).
Recommendations for Africa’s preparedness and 
response
As the COVID-19 cases continue to increase across the world 
(Zarocostas, 2020) including Africa (Makoni, 2020), governments, 
scientists, and personnel from the medical fraternity must urgently 
enhance preparedness. COVID-19 infections in Africa are rapidly 
rising, with the virus spreading to dozens of countries within 
weeks, countries are moving from preparedness to response 
(WHO, 2020a). The already overwhelmed and fragile health 
systems in Africa may not be in a good position to handle a 
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Figure 5. The antiviral activities of the test drugs against 2019-nCoV in vitro. Vero E6 cells were infected with 2019-nCoV at an MOI 
of 0.05 in the treatment of different doses of the indicated antivirals for 48 h. The viral yield in the cell supernatant was then quantified by 
qRT-PCR. Cytotoxicity of these drugs to Vero E6 cells was measured by CCK-8 assays. The left and right Y-axis of the graphs represent mean 
% inhibition of virus yield and cytotoxicity of the drugs, respectively. The experiments were done in triplicates. Reproduced under the terms 
of the Creative Commons CC BY license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original 
work is properly cited (Wang et al., 2020).
severe outbreak of this nature. This section of the paper suggests 
recommendations and highlights some of the optimistic response 
that Africa is deploying in response to the virus.
Reinforcing public health infrastructure and capabilities
There is a need for a concerted and multi-sectoral approach to 
increase the overall level of preparedness of health infrastructure 
and capacity in Africa. The preparedness should include, well 
trained sufficient manpower, quick response rates, the availability 
of critical medical logistics; products, pharmaceuticals, masks, 
testing kits, hospital beds and protective gear. In addition, labo-
ratories with the needed standardized biosafety levels as well as, 
available and efficient isolation, referral hospitals and treatment 
facilities need to be identified and made ready to receive patients 
(Government of Kenya, 2020). In the case of Kenya, transport and 
mobile isolation units were expanded into temporary isolation 
treatment facilities to tackle cases of the virus (Business Insider 
SA, 2020). There is also a dire need to train doctors and nurses 
as well as rapidly recruit more to expand the personnel number 
to manage infected cases, with the support of international 
organizations and local private entities. The WHO has deployed 
40 experts in 10 countries to support treatment, infection, control 
and prevention, coordination, community engagement, laboratory 
disease control and surveillance. Further assistance has helped 
countries in diagnostic capacity building (Business Insider SA, 
2020). Prevention and control measures at both the community 
and healthcare facility levels will be critical (WHO, 2020a).
Early detection of cases
A critical first step is early detection of the virus to limit 
human-to-human transmission that could ultimately negatively 
influence treatment capacity (Makoni, 2020). It is also imperative 
that the African continent prepares to create capacity for isolation 
and treatment of affected individuals. Early detection in African 
countries has been supported by the WHO, that have provided 
COVID-19 testing kits, strengthening surveillance in communities 
and training dozens of health workers. However, this is by 
no means sufficient to the need that lies ahead (WHO Euro region, 
2020).
In most countries, there are one or two designated centers 
‘accredited’ for testing COVID-19 cases. This will mean a lot of 
samples must be shipped from long distances across the country. 
It is recommended that national research centers liaise with 
·½»ʸʹÅ¼ʹʸ
Æ»Ä»É»·È¹¾ʹʷʹʷƑʺƓʸˀ·ÉÊËÆº·Ê»ºƓʸʿʹʷʹʷ
university molecular laboratories (of which there could be several 
across the country) and other high level research molecular 
research laboratories available within their countries to increase 
their capacity to support testing. This will go a long way to 
determine the community burden and increase the overall capacity 
of the country to respond better in subsequent outbreaks.
Health surveillance systems and sample testing services
Tracking and health surveillance systems are important for 
outbreaks. Before 4 February 2020, the National Institute of 
Communicable Diseases in SA and the Institut Pasteur in Senegal 
were the only referral laboratories in Africa capable of 
COVID-19 sample testing. Currently, 47 countries in the WHO 
African region have COVID-19 testing and screening facilities 
in place (WHO, 2020d). The AU’s Center for Disease Control, 
CDC, have also championed efforts to boost the capacity of 
African member states in testing and screening COVID-19 
(Africa News Agency (ANA) Reporter, 2020). Although the WHO 
African region has donated PPE to the Ministry of Health in 
Ghana and to some other African countries as part of efforts to 
support COVID-19 Outbreak Response (WHO, 2020c), much 
more has to be done. Beyond testing is the capacity of the 
countries to continue tracking the suspected cases including 
identifying those who potentially go into hiding due to associated 
stigma as such  cases have potential of escalating the spread of 
the virus.
Controlling ports of entry
Preparedness should include effective and efficient surveillance 
at all ports and points of entry into each country. Africa is the 
leading commercial partner for China, and therefore air travel 
between China and the continent increases the importation of 
the virus in Africa (Gilbert et al., 2020). While measures have 
been put into place for prevention and control of Chinese impor-
tation (Le Monde Afrique, 2020; WHO, 2020d), with local 
transmission, the detection, prevention and control are of 
concern and requires accelerated identification of doubtful cases, 
isolation and transfer of individuals, diagnosis, tracing, and 
potential contact follow-up, as well as increased surveillance 
(Gilbert et al., 2020; WHO, 2020d). For example, to prevent the 
outbreak and spread of COVID-19, Kenya has already banned 
slaughter, the export of donkeys and all flights from China. The 
Kenya-Uganda land border has been closed to all pedestrians 
and vehicles, with the exception of cargo trucks. Other countries 
have drawn lessons from the 2014 Ebola virus, where more than 
11 000 people died. For example, the Democratic Republic of 
the Congo strengthened points of entry screening, partner 
coordination structures in readiness and upgrading of isolation 
units in management of suspected cases (Kazeem, 2020).
Importation risk mitigation
Due to the high volume travel links mentioned previously, WHO 
has prioritized support for 13 African countries, namely South 
Africa, Uganda, Kenya, Ghana, Nigeria, Zambia, Ethiopia, 
Algeria, the Democratic Republic of the Congo, Mauritius, Angola, 
Tanzania and Cote d’Ivoire (Makoni, 2020). Despite Egypt hav-
ing high risk SPAR and IDVI scores and pinpointed as the airport 
on the African continent with the highest passenger load from 
Chinese affected areas, the country was not named among the 
WHO prioritization list (Lai et al., 2020). In addition, miss-
ing from the list was Morocco, despite the country having 
moderate risk scores (Gilbert et al., 2020). It is recommended 
that the WHO expand their support to all African nations who 
need support to deal with the COVID-19 cases.
Regional coordination platforms
Coordination platforms are crucial to ensure contingency and 
emergency plans are present, operational structures with clear 
communication channels exist, and resources are adequate and 
available for impending threats (Ayebare et al., 2020). This can 
enable timely intervention to mobilize domestic and international 
resources to operationalise preparedness plans and response 
efforts. The WHO plays a vital role in coordinating efforts for 
preparedness of local outbreaks (WHO, 2020a). However, the 
utilization of existing structures is also critical. For example, as 
of 3 February 2020, the Africa Task Force for COVID-19 was 
established by the African Centre for Disease Control and 
Prevention (African CDC, 2020). Together with WHO, the Africa 
CDC is working on point of entry screening, prevention and 
control of infections at healthcare facilities, clinically managing 
severe COVID-19 infections, engaging communities, providing 
risk communication and laboratory diagnosis (WHO, 2020b). 
The Africa CDC coordination body has already been pivotal in 
establishing testing capacity for SARS-CoV-2 in approxi-
mately 40 African countries within one month of declaration of a 
“Public Health Emergency of International Concern” (PHEIC) 
(Ayebare et al., 2020). However, the Director of Africa CDC 
reiterates the growing concern of the COVID-19 threat to Africa 
at different levels, namely, economic growth, security and social 
dynamics (Makoni, 2020).
Domestic coordination structures
Domestic examples of coordination have also already been 
seen. For example, in January 2020, the Federal Government of 
Nigeria (FGN) approved funds for preparedness for the Federal 
Ministry of Health (FMoH) for COVID-19. A multi-sectoral 
Coronavirus Preparedness Group led by the Nigeria Centre for 
Disease Control and National Emergency Operations Centre 
(EOC) has been set up by the FMoH to work closely with other 
stakeholders to respond to COVID cases and implement solid 
control measures (Federal Ministry of Health, 2020). Similarly, 
the Government of Kenya (GoK) issued an executive order in 
February 2020 to establish a framework for upscale and co- 
ordinate Kenya’s preparedness and national response to the 
threat of COVID-19. As part of this, Kenya has established the 
national emergency response committee (Government of Kenya, 
2020). The committee’s mandate is to coordinate the country’s 
preparedness, prevention and response, coordinate capacity 
building of medical personnel to respond to the threat, enhance 
surveillance at all ports and points of entry in Kenya, coordinate 
preparation of national, country and private isolation and 
treatment facilities, coordinate the supply of critical medical 
products/supplies, pharmaceuticals, masks, testing kits, and 
other protective gears (Government of Kenya, 2020). Similar 
coordinating entities will need to be set up elsewhere.
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Financing
Fast accelerator funding should be made available to strengthen 
measures to ensure control and containment of an outbreak 
quickly. The financing would cover the procurement of diagnostic 
kits, protective gears, building and upgrading of laboratories, 
hospital beds and payments of personnel. This places a further 
burden on the already lean purses of most African countries. To 
date, the WHO has donated Personal Protective Equipment as 
part of efforts to support COVID-19 Outbreak Response, to the 
Ghanaian Ministry of Health, including 300 swabs, 500 RNA 
extraction, 1000 test kits, 9000 surgical masks, 180 goggles, 800 
face shields, 350 N95 masks, 9200 examination gloves and 750 
gowns. The WHO has also been supporting the Ghana Health 
Services by providing technical support for preparedness and 
response to COVID-19. The support included coordination and 
case management as well as capacity building (WHO, 2020c).
Governments are also starting to put in place financing schemes 
to support small to medium sized businesses, and funds 
to cushion the financial shocks experienced particularly 
during country lockdowns. For example, South Africa has 
established the Solidarity Fund, Debt Relief Fund, and Busi-
ness Growth/Resilience Facility as well as 42 million Rand 
investment in the health sector alone (Dlothi, 2020).
Private philanthropists including the Oppenheimers and the 
Ruperts, two of the wealthiest families in the country, have 
each donated R1 billion towards the relief fund. Religious 
organizations, such as the AwqafSA, the Muslim Judicial Council, 
Sanzaf and Islamic Relief South Africa, have collectively donated 
R1million for low-income communities, and particularly those 
who derive their income from the informal sector. Funds will be 
used to provide aid via the donations in the form of hygiene and 
sanitation kits, water and non-perishable food items immediately 
during the 21-day lock-down and to stimulate recovery afterwards 
(Thebus, 2020). A unit, called the Vulindlela unit is also being set 
up in the Ministry of Finance, who will evaluate both the 
government and the private sector in creating the required 
structural reforms (Stoddard, 2020). Many more efforts such as 
these will be needed - with the support of all sectors of society, as 
millions struggle from impacts of likely economic recessions.
Efficient and constant sensitization and community 
engagement
Before the emergence of the first cases in Africa, efforts were 
made to sensitize the general population about the virus, 
taking personal preventive measures such as avoiding crowded 
gatherings, preventative hygiene measures, social distancing, 
self-isolation, regular and thorough hand washing using soap and 
water, using hand sanitizer (alcohol-based), and wearing face 
masks. These orientations notwithstanding, a negligible propor-
tion of the population adopted these measures. Awareness raising 
should be scaled up, using social media platforms and work to 
curb the misinformation and myths about the virus (Shields, 2020). 
There will also be a need for increasing the capacity of local 
disaster risk management committees and youth groups for 
emergency responses, setting up mobile laboratories and clinics, 
and increasing the legitimacy of local chiefs or queen mothers 
and section heads, and religious leaders to disseminate timely 
information. The efficient and constant orientation of the citizens 
is needed, including in different vernacular languages, for the 
non-literate and disabled.
Reducing xenophobia and protecting against gender-based 
violence
The World Health Organization cautions against “actions that 
promote stigma or discrimination” when conducting national 
response measures to the outbreak managed to avoid potential 
racially aggravated assaults or violence. There is also a need for 
health officials to speak openly and respond to the concerns of 
communities to avoid antagonistic attacks (STAT, 2020). Social 
services will need to develop material and refine existing materials 
to ensure the safety and wellbeing of women and children 
against gender-based violence during lockdowns. Telephonic 
counselling will become more important, along with awareness 
raising using telephone applications in the court and for jus-
tice support. Facilities should be provided for trauma contain-
ment counselling. New forms of safety planning will need to 
be developed (Mosaic, 2020).
Communicable disease hotlines
Communicable diseases hotlines should be put in place in every 
country, to respond to worried callers, requesting advice on safety 
and understanding the symptoms. For example, South Africa’s 
largest hospital group, Netcare, has refocused its communicable 
diseases hotline on COVID-19. In Algeria a call center has been 
set up in the capital Algiers to improve early detection and help 
contain the spread of the disease. This can be encouraging to 
people to avoid the spread of COVID-19 by taking correct 
measures, and countering false information in the public 
domain (WHO, 2020e). Strengthening the national capacity for 
disseminating alerts should also be a priority.
Provision of water and sanitation, particularly in informal 
settlements
Washing hands regularly or using alcohol-based sanitizers is a 
challenge for people with limited access to water. Three billion 
people across the world do not have access to handwashing 
facilities. Meanwhile, 33 of the top 42 countries that have the least 
access to hand-washing facilities are found in Africa (Kashiwase, 
2020). Municipalities urgently need to prioritize the installation, 
repair and maintenance of access to clean, affordable water, 
increase the number of standpipes and install water tankers in 
informal settlements. Examples have already been seen in some 
parts of the continent, such as in South Africa, which is planning 
to assist over 2,000 communities by distributing water tanks at 
2,901 water collection points (DeKlerk, 2020).
Temporary shelter for the homeless
Many homeless people will need places to stay during the 
lockdown events. Temporary shelters will need to be identified to 
accommodate these people. This has been the response by Cyril 
Ramophosa, the president of South Africa (Mail & Guardian, 
April 2020). Incentives must be created so the homeless do not 
feel forced into those facilities, with concerns of living in close 
proximity in full boarding homes, with the potential to be exposed 
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to others with drug and alcohol addictions. During this time, 
authorities should support the development of soft skills to help 
them integrate back into their families and communities (Daily 
Maverick Team, 2020).
Increasing access to telecommunications
To ensure the access to telecommunications of poor, rural 
communities, special thought will need to be given to the benefits 
of logistically organized, centralized delivery routes with low 
packaging. Moreover, studies have shown many Africans are 
apprehensive to purchase online due to fraud and delivery 
difficulties. This should be preempted and managed through 
training, along with infrastructure development to scale up internet 
penetration in marginal communities (Makhitha & Dlodlo, 2014).
Changing behavior patterns in the long term to reduce 
carbon emissions
Our study has also shown COVID-19 may affect the way 
economic stimulus affects how emissions will evolve in the 
coming years. If behaviors preferences persist beyond the 
pandemic, this may reduce emissions and may contribute to the 
Africans’ decarbonization process. Nations need to take seriously 
the potential opportunities to change and sustain measures to 
reduce air pollution, increase the presence for biodiversity, among 
other activities, as has already been observed in many parts of the 
world, to potentially mean a turn-around in the long-term trend 
(Henriques, 2020; Myllyvirta, 2020).
Physical activity and mental health
To ensure public health recommendations for social isolation 
quarantine should recommend a regular activity, going outside 
and exercising in unpopulated areas during quiet periods, and 
ways to maintain social connectivity, such as through 
computers, affordable internet connectivity, and training in 
digital training. Physical activity is vital for mental health and 
protecting the immune system from the effects of stress, arguably 
more so during self-isolation. Governments must support citizens 
in lockdown with guidance on how to exercise at home or 
provide time to exercise outdoors once a day (Cassata, 2020).
Reducing food insecurity
Interventions must be put in place for vulnerable populations, 
including low-income communities, senior citizens, and disabled 
populations to receive appropriate healthy and nutritious food 
assistance and avoid hunger. Distribution centers and supermarkets 
for fresh produce should also scale up plans to deal with increased 
demand from ‘panicked’ shoppers. Moreover, planning across 
the supply chain is needed to avoid food insecurity. In addition to 
other health services, countries across Africa must scale up social 
safety nets that are flexible to shocks (Beltrami, 2020).
Potential targets for the development of therapies
Current treatment options available to healthcare professionals 
fighting the COVID-19 pandemic are scarce given that the 
pathogenesis of the virus is not fully understood yet. The CoV spike 
glycoprotein is a key target for vaccines, therapeutic antibodies 
and other diagnostics (Wrapp et al., 2020). The presence of the 
densely glycosylated spike (S) protein facilitates the entry of the 
SARS-COV-2 into host cells (Wrapp et al., 2020). The S protein 
is present in a metastable prefusion trimer conformation which 
undergoes dramatic rearrangement of its structure enabling fusion 
of the viral membrane with the host cell membrane. Binding of 
the S1 subunit to the host-cell receptor triggers this process. This 
destabilizes the pre-fusion trimer causing release of the S1 subunit 
and transition of the S2 subunit into a stable post-fusion 
conformation (Walls et al., 2017). Indeed, the S protein plays an 
indispensable function and thus represents a potential target for 
antibody mediated neutralization and can further guide vaccine 
design for the treatment of the COVID-19.
Structural modeling of S protein indicated strong interaction of 
the human ACE2 molecules with SARS-COV-2 (Xu et al., 2020). 
Chen & Du (2020) identified 5 active compounds namely Baicalin, 
Scutellarin, Hesperetin, Nicotiamine and Glycyrrhizin and carried 
out molecular docking studies to predict their binding capacity 
to ACE2. As can be noted from Table 2, Scutellarin had 
the highest binding affinity to ACE2 compared to the remaining 
molecules.
In general, viruses enter cells through a process known as 
receptor mediated endocytosis and recent studies suggested that 
ACE2 in COVID-19 may be the receptor involved in infecting lung 
cells. The surface protein ACE2 is located on cells in the kidney, 
blood vessels and importantly in lung AT2 alveolar epithelial cells. 
AP2-associated protein kinase 1 (AAK1) is a known regulator of 
endocytosis. Hence a potential way of preventing transmission of 
the virus into human cells could be via the disruption of AAK1 
(Richardson et al., 2020). Amongst the 378 AAK1 inhibitors in 
Table 2. Summary of molecular docking of 
Baicalin, Scutellarin, Hesperetin, Nicotiamine 
and Glycyrrhizin with ACE2 (Chen & Du 2020).
Compound ǻ G/ (kCal/mol) Potential 
binding sites
Baicalin -8.46 ASN-149 
ARG-273 
HIS-505
Scutellarin -14.9 GLU-495 
UNK-957 
ARG-482
Hesperetin -8.3 TYR-613 
SER-611 
ARG-482 
GLU-479
Nicotiamine -5.1 ARG-518 
GLU-406 
SER-409 
GLN-522 
GLN-442
Glycyrrhizin -9 ARG-559 
GLN-388 
ARG-393 
ASP-30
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the knowledge graph generated by the company BenevolentAI, 
six were found to inhibit AAK1 with high affinity. These included 
anti-cancer drugs such as sunitinib and erlotinib, which can cause 
serious side effects and therefore were not considered further. The 
janus kinase inhibitor baricitinib, on the other hand, was shown 
to inhibit AAK1 in doses as low as 2 or 4 mg daily suggesting its 
possible use in trials (Richardson et al., 2020).
Current efforts are being geared towards drug repurposing of 
already FDA approved drugs as well as the virtual screening for 
molecules available from chemical libraries. Insilco Medicine 
designed and started the generation of novel drug-like inhibitors 
of 2019-nCoV using three of its validated generative chemistry 
approaches (Zhavoronkov et al., 2020). The selected target was 
the C30 endopeptidase (3CLP) which is a homodimeric cysteine 
protease that cleaves polyproteins into individual polypeptides 
and plays a vital role in replication and transcription of the virus. 
Various virtual structures with high 3D complexity were generated 
which can then be used in computer modelling simulations or to 
synthesize and test the compounds in vitro.
Potential for development of point of care (POC) diagnostics
Early diagnosis of COVID-19 is critical to timely management 
of patients and control of spread of the disease. The key to this 
fight is to track, test and contain infection clusters. Indeed, this 
step helped to reduce the number of mortalities associated with 
COVID-19 in Germany whereby only 0.4% of people who have 
been tested positive for the virus have succumbed to the latter 
in contrast to 4.3 % in France (MarketWatch (2020)). It was 
recently pointed out that people showing mild or no symptoms 
of COVID-19 can actually be harboring high viral loads in the 
throat and may spread the virus through ‘viral shedding’ (Woelfel 
et al., 2020).
However, the current tools; RT-PCR and radiological imaging, 
are not adequate to address point of care diagnosis especially in 
low resource settings that characterize sub-Saharan Africa. Indeed, 
as the pandemic situation evolves with control goals focusing 
both containment and mitigation (Parodi & Liu, 2020; WHO, 
2020), capacity for wide scale diagnosis at most if not all levels 
of health care systems will be vital for long-term control. Again, 
as treatment solutions for the disease become available, prompt 
diagnosis will be essential in enabling prompt treatment of cases 
and determining isolation/quarantine decisions.
RT-PCR diagnostic capacity is limited in most African countries, 
with 1-3 labs in 40 countries as on 25th Feb, 2020 with 
WHO- Afro and AFTCOR keen to increase this number to cover 
all the 55 African countries (Nkengasong & Mankoula, 2020). 
However, the changing epidemiology of the disease calls for 
changes in strategies in diagnosis and several countries have 
tried several strategies. For instance, South Korea and USA are 
implementing drive-through testing, that allows for in-car 
oro-pharyngeal sampling and on site RT-PCR (Cohen, 2020). The 
whole process takes approximately 2 hours from sampling to 
result. However, this leaves out the vast non-driving population, 
and adds to queuing time. After the decision is shared with cli-
ent, clinical follow up may be challenging due to the fact that the 
client leaves the site and does not return to the site for follow up.
Radiological testing using chest computed tomography 
(CT)-scans, has been shown to be highly sensitive at 97% 
but poorly specific at 48% in a Chinese study (Ai et al., 2020). 
CT-Scans unlike RT-PCR enables shorter result times especially 
with the possibility of Artificial Intelligence (AI) enabled image 
analysis and interpretation. But this technology is highly lim-
ited to level 5 and 6 hospitals in most African countries, with 
very low numbers of radiologists and poor adoption of AI. 
This technology may not be optimal in addressing the covid-19 
diagnostics challenges in Africa.
What is the way forward? As the focus is on point of care testing, 
it will be critical to ensure that the ASSURED characteristics 
of an ideal diagnostic test, i.e. Affordable, Sensitive, Specific, 
User-friendly, Rapid, Equipment-free, and Easy Delivery to those 
in need are met (Mabey et al., 2004; Urdea et al., 2006). These 
criteria are practical driving forces that are useful in the design, 
development and utilization of a point of care test for COVID-19. 
Potential strategies will include serological point of care testing, 
molecular-isothermal amplification such as RT-LAMP, CRISPR 
based SHERLOCK (Specific High Sensitivity Enzymatic Reporter 
UnLOCKing) and Helicase dependent amplification with paper or 
calorimetric visualization (Zhang et al., 2020). LAMP is already 
in use with the Genie III device already adapted for POC for TB 
and several other infectious diseases but has largely been limited 
to research studies. Indeed, the Xpert® Xpress SARS-CoV-2 
test by Cepheid, which uses the GeneXpert platform has received 
emergency use approval by the FDA (Cepheid®, 2020). Wide-
spread use of this technology in Africa will make testing more 
accessible in the near future. This is a good time for countries, 
university research centers, biotechnology companies, and startups 
to take up the challenge and develop similar technologies 
in order to bring these devices to the peripheral healthcare 
system as soon as possible. However, innovative funding 
mechanisms need to be developed to enable development of 
point of care diagnostics research, prototyping, and implementa-
tion research as associated business and regulatory ecosystems 
in Africa, to reduce turn-around-time and reliance on solutions 
from out of Africa in such situations as presented by COVID-19.
While there are efforts towards preparedness in some countries, 
nothing is known about the readiness of some African countries 
towards curtailing COVID-19. According to the WHO Regional 
Director for Africa, there remain critical gaps as countries prepare 
for the readiness of an outbreak. The WHO Africa head identified 
it would be very challenging if the virus spread rapidly to African 
cities with no facilities to contain and treat people (Shaban, 2020a). 
Since the beginning of the pandemic, the African region is wit-
nessing a rapid rise in the confirmed COVID-19 cases. This begs 
the question of how prepared are we in dealing with pandemics and 
epidemics on the African continent?
Considering the dramatic evolution of the COVID-19 pandemic, 
the WHO in the African Region has called on countries to imple-
ment critical actions in the next two weeks while there is still 
time to prevent the outbreak in the region from overwhelming 
health services (WHO, 2020f). While there are many interventions 
currently underway, as indicated in Table 3, there remains many 
gaps.
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Table 3. Examples of national preparedness interventions of countries in each African region on 30 March 2020. (DFID: UK Department of International Development; WHO: World Health Organization; NICD: National Institute For 
Communicable Diseases).
Country Region Total 
cases
Health surveillence Sensitization Coordination platforms Financing
Health infrastructure 
and capabilities Ports of entry Social protection Water and hygiene provision Social distancing References
South 
Africa Southern 1280
National Institute for 
Communicable Diseases 
(NICD) supports the core 
capacity for surveillance 
in response to outbreaks. 
10,000 workers going into 
informal settlements to 
test people.
Social distancing, self-
isolation, alcohol-based 
hand sanitizers, wearing 
face masks, avoidance of 
crowd gathering, raising 
awareness, social media 
awareness and dialogues
Ministry of Health, 
NICD, WHO Africa, 
Africa CDC
Solidarity Fund, 
money received 
from SA richest 
families- Ruperts and 
Opperheimers, and 
religious organizations 
such as the Muslim 
Judicial Council, 
Awqaf SA, Sanzaf and 
Islamic Relief South 
Africa
Netcare, SA’s largest 
hospital group, refocused 
its communicable 
diseases hotline. 
Transport and mobile 
isolation units expanded 
into temporary isolation 
treatment facilities. 
Doctors and nurses of the 
Netcare group received 
training in managing 
such cases.
Enhanced 
surveillance 
at ports of all 
travellers from 
Asia- especially 
China. 
International. 
airports remain as 
the only ports of 
entry with direct 
flights from Asia
Gender-Based 
Violence Command 
Centre provides 
support for women 
and children at risk 
for abuse during 
the 21-day national 
lockdown.
Interventions on water 
services infrastructure, with an 
intention of improving water 
supply, access to sanitation 
and sanitizing of public 
spaces (e.g., government 
provision to 2000 communities 
of water tanks).
21 day lockdown that 
started at midnight 
26 March 2020
Thebus, 2020; 
DeKlerk, 2020; 
NICD, 2020; NDoH, 
2020; Thebus, 2020; 
Business Insider 
SA; Maphanga, 
2020; SA 
Government, 2020; 
SocialProtectionOrg, 
2020
Cameroon Central 139
Surveillance system set 
up by the Ministry of 
Health, supported by 
WHO and US CDC. Jack 
Ma Foundation and Alibab 
Foundation founder Jack 
Ma donates 20,000 test 
kits, 100,000 masks 
and 1,000 medical-use 
protective suits
Full closure of educational 
institutions. Mass 
gatherings banned. public 
spaces closed. Measures 
are being put in place for 
vulnerable groups- elderly, 
prisoners. Sensitization 
and detection campaigns 
to be held in April 2020
Ministry of Health, 
WHO Africa
Coronavirus Relief 
Fund- set up by 
Social Development 
International
Hospital isolation and 
treatment centres have 
been set up for people 
who meet the case 
definition for Covid-19 at 
Yaoundé Central Hospital, 
Laquintinie Hospital in 
Douala, Garoua Regional 
Hospital, and Kribi 
District.
Full sea, land and 
air border closures 
indefinitely; only 
cargo planes 
allowed into 
country
Measure are being 
put in place for 
vulnerable groups- 
elderly
International Committee of 
the Red Cross delivering 
soaps and other household 
necessities to 650 families. 
Plans are to also deliver 22 
tons of soap and 44 000 jerry 
cans to communities and 
prisons.
Schools closed and 
all prayers to be 
conducted at home.
ANA Reporter, 2020; 
Tih, 2020; APO, 
2020a; SDI, 2020; 
Kindzeka, 2020; 
ICRC, 2020
Nigeria Western 111
Only suspected cases 
are tested as there are 
shortages of testing 
materials.
Mass media campaign on 
the need for physical and 
social distancing, self-
isolation, alcohol-based 
hand sanitizers, wearing 
face masks, maximum 
of 50 people in crowd 
gatherings.
Nigeria Centre for 
Control of Diseases. 
Federal Ministry of 
Health.
The Federal 
Government released 
1.5 billion Naira ($42 
Million) to fight the 
scourge, Private 
organizations as 
well as individuals 
have made generous 
contributions towards 
purchase of materials 
and conversion of 
some buildings to 
isolation centres.
100-bed Infectious 
Disease Hospital in 
Lagos is fully equipped to 
handle COVID-19 cases. 
Training new recruits 
and existing personnel 
to handle treatment of 
cases, contact tracing, 
etc.
The Federal 
Government shut 
all ports of entry to 
Nigeria effective 
March 21st
None
The provision of hand sanitizer 
is only available at some 
public buildings. The prices of 
the hygiene materials such as 
nose masks and sanitizers are 
now costly
The federal 
government has 
introduced a total 
lockdown for 14 days 
at the first instance 
in Lagos and Abuja, 
where 90% of the 
cases are. Other 
states have shut 
down interstate 
travel.
Nigeria Centre for 
Disease Control, 
2020; CNBC Africa, 
2020.
Kenya Eastern 70
Conducting random 
temperature screenings 
in spaces frequented by 
the general public. China 
donates 12,000 testing 
kits. 1005 people have 
been tested.
Aga Khan national 
hospital, University of 
Nairobi and others have 
implemented a public 
awareness campaign. 
Ministry of Health, County 
Governments, Kenya 
Red Cross, and others 
sensitizing communities 
on how to maintain basic 
hand hygiene, and safe 
food practices, training 
volunteers to raise 
awareness in informal 
settlements.
National emergency 
response committee; 
Kenyan Centre for 
Disease Control.
Reduced Income Tax 
Rate (Pay-As-You-
Earn) from 30% to 
25%, Resident Income 
Tax (Corporation Tax) 
from 30% to 25%, 
and turnover tax rate 
from 3% to 1% for 
all Micro, Small and 
Medium Enterprises. 
Kenya’s largest teleco, 
Safaricom fee-waiver 
on M-Pesa, to reduce 
the physical exchange 
of currency.
Identified available and 
efficient isolation, referral 
hospitals and treatment 
facilities and made ready 
to receive patients. 
Transport and mobile 
isolation units expanded 
into temporary isolation 
treatment facilities. 
Hospitals have set up 
120 beds in Mbagathi 
Hospital preparation for 
possible cases. Capacity 
building of health workers 
and staff.
Banned 
international 
flights. Kenya-
Uganda land 
border closed to 
all pedestrians 
and vehicles, 
except cargo 
trucks. Banning 
international 
meetings.
Government 
appropriated Ksh. 
10 Billion to the 
elderly, orphans and 
other vulnerable 
people through 
cash-transfers by the 
Ministry of Labour 
and Social Protection. 
The Ministry of 
Agriculture will 
distribute cereals to 
the poor. Religious 
organisations and 
businesses calling for 
food donations.
Government set up water 
washing stations in informal 
settlements. UK DFID and 
Unilever donated funds for 
providing hygiene products 
and raise awareness.
Nationwide curfew 
(7pm to 5am). 2000 
people in mandatory 
quarantine.
Government of 
Kenya, 2020; Bright 
2020; Degun, 2020; 
Ssebwami 2020; 
Harper, 2020
Egypt Northern 609
Activation of different 
acute respiratory infection 
(ARI) surveillance systems 
. 17 laboratories across 
the country and, with 
an additional four and 
university laboratories 
also wanting to engage. 
With WHO support, Egypt 
can now conduct 200 
000 tests.
Sensitization campaigns 
responses to the 
pandemic, quarantine 
processes, development 
of risk communication 
strategy. Orientation 
workshops for healthcare 
workers.
Department of 
Epidemiology and 
Surveillance (DES) 
for the Ministry of 
Health, WHO, Egypt 
Field Epidemiology 
Training Program 
(FETP)
Egyptian government 
gives the Health 
Ministry 6.4 billion 
dollars to fight 
coronavirus
Egypt has ½ beds for 
every 1000 individuals., 
fragile hospitals and 
public health systems, 
only 4% of GDP spent 
on health infrastructure. 
Training of healthcare 
workers at the national 
and peripheral levels on 
the COVID-19 pandemic
all air traffic 
at airports 
suspended from 
March 19 until 
March 31; closure 
of some land 
borders
The Ministry of 
Manpower gave 
one-time $31 each to 
all registered irregular 
workers in Egypt to 
ease the burden of 
Covid-19
Mass distribution of sanitizers. 
In Dakahliya governorate, 
600 tons of sanitizers were 
distributed in its cities and 
neighborhoods
14-day nation curfew 
from 7pm to 6am 
(24 March 2020); 
possible lockdown
APO, 2020b; 
Rezvani, 2020; 
Mourad & Lewis, 
2020; Mezran  
et al., 2020; Khalifa, 
2020; APO, 2020a; 
SocialProtectionOrg, 
2020; TEPHINET, 
2020; EgyptToday, 
2020
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Future directions for research and practice
As SARS-CoV-2 virus is an efficient contagion, calculated 
measures are required to control the COVID-19 pandemic. The 
peculiarities of African populations should be considered as 
scientists race towards clinical investigation of chloroquine, 
hydroxychloroquine, remdesivir and other therapeutic options. For 
instance, following widespread resistance, many African countries 
halted the use of chloroquine as an antimalarial. It is however 
not clear if existing chloroquine pressure has any impact on the 
antiviral benefit of the drug in malaria-endemic regions. In 
addition, the safety, reactogenicity and immunogenicity of 
vaccine candidates should be tested within an African context. 
Comparative analysis of the breadth of immune response in 
asymptomatic carriers and symptomatic survivors of COVID-19 
will provide information on specific anti-disease antibodies and 
the possibility of a re-infection with the virus after full recovery. 
As efforts to combat this current wave of COVID-19 begin to 
yield expected outcomes, health experts should be interested in 
exploring ways to prevent or minimize the impact of a poten-
tial rebound. There is a need to understand the genetic and 
evolutionary dynamics of the virus, protect vulnerable popula-
tions, conduct aggressive contact tracing and physical distancing to 
salvage Africa’s health systems. Rapid, affordable and field- 
adaptable diagnostics will be required at borders and ports for 
real-time on-the-spot detection of asymptomatic and symptomatic 
cases. African governments should prepare a financial warchest 
and infrastructural capacity to support frontline healthcare 
workers. Indeed, the partnership of African economists, investors, 
scientists, tech-experts, health practitioners and political stake-
holders will be required to slow down the COVID-19 trajectory on 
the continent.
Conclusion
Based on our synthesis of the current evidence, while there are 
plans for preparedness in several African countries, there are 
limitations. There is a need to address the identified gaps, more 
specifically the challenges and concerns must be a priority. There 
have to be multi-sectoral efforts from the science, education, 
medical, technology, communication, business, and industry 
sectors, as well as local communities, that can collaboratively 
work to assist countries as this pandemic continues to challenge the 
continent and the world further. The actions taken or failed to be 
taken by African countries in the coming weeks and months will 
determine how well African countries will fare in containing the 
spread of COVID-19.
In the concerted effort to develop potential COVID-19 treatment 
regimens, effective drugs and vaccines, a range of small molecules 
and biologics targeting the complex molecular interactions 
involved in the virus infection and replication processes are being 
considered. Since the development of new drugs/vaccines is a 
lengthy process, the current strategy being adopted for immediate 
treatment of COVID-19 infected individuals is drug repurposing 
whereby previously FDA approved drugs are being used to tar-
get COVID-19 receptor proteins, proteases etc (Liu et al., 2020). 
Policy makers should facilitate the participation of their respective 
countries in ongoing international COVID-19 clinical trials such 
as the Solidarity trial so that more participants may be recruited 
thereby giving a more reliable and representative outcome.
There currently exist PCR platforms that are quick and field 
amenable such as LAMP and GeneXpert, which have already 
been approved by WHO for the diagnosis of tuberculosis. Countries 
can use their molecular biology departments to adapt these tests 
to test for COVID-19. This will be a sure way to improve 
accurate diagnosis turnover rate and also bring it to the community 
level.
As the understanding of the virus of the scientific community 
grows, along with government interventions of preparedness, we 
recognize this is a rapidly evolving area of study as new informa-
tion becomes available on a daily basis, and there are therefore 
limitations, warranting deeper investigation. Results should be 
seen as complementary, and informing current and future strategies 
in the light of new evidence. We hope that actors in various sectors 
of society will consider these recommendations, among a suite of 
many, as well as their potential trade-offs, so that Africa is better 
prepared to combat the COVID-19 pandemic.
Data availability
Underlying data
All data underlying the results are available as part of the article 
and no additional source data are required.
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